WilliamC.HuangMDFACS (He/Him)

Minimally Invasive Surgery, Surgical Oncology

Professor of Urology and Radiology Vice Chairman (Clinical Affairs), Department of Urology Chief of Urology, Tisch Hospital Co-Director, NYU Robotic Surgery Center NYU Hospitals Center

Join to view full profile

Dr. Huang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Huang's full profile

Already have an account?

Office
222 East 41st Street
12th Floor
New York, NY 10017

Summary

Dr. William Huang is a New York-based urologist specializing in minimally invasive surgery and surgical oncology. He completed his medical education at Sidney Kimmel Medical College and underwent extensive residency and fellowship training at Lahey Clinic and Memorial Sloan Kettering Cancer Center. Serving as the Chief of Urology at Tisch Hospital, NYU Langone Hospitals since 2016, he has expertise in areas including renal cell carcinoma and prostate cancer. Dr. Huang's research is reflected in multiple publications and he is actively involved in clinical trials, such as a Phase 3 study on non-muscle-invasive bladder cancer. His accolades include being named America’s Top Doctor for Cancer and a Top Doctor by New York Magazine.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2004 - 2007
Lahey ClinicResidency, Urology, 2000 - 2004
Lahey ClinicResidency, Surgery, 1998 - 2000
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1998

Certifications & Licensure

NJ State Medical License 2023 - 2025
NY State Medical License 2004 - 2025
MA State Medical License 2000 - 2004
ME State Medical License Active through 2003
PA State Medical License 2000 - 2002
American Board of Urology Urology
Society of Urologic OncologyFellow

Awards, Honors, & Recognition

America’s Top Doctors for Cancer Castle Connolly, 2018-2021
Top Doctors New York Magazine, 2016, 2018-2021
Regional Top Doctor Castle Connolly, 2014-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer Start of enrollment: 2022 Mar 01
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive N...
Jacob Taylor, Ashish M Kamat, Drupad Annapureddy, Zine-Eddine Khene, Jeffrey Howard
European Urology Oncology. 2025-04-01
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies.
Drupad Annapureddy, Jacob I Taylor, Ashish M Kamat, Michael A O'Donnell, Jeffrey Howard
European Urology Focus. 2025-02-07
Real-World Treatment Patterns and Outcomes in Patients With Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicountry Medical ...
Girish S Kulkarni, Thomas Guzzo, Philip H Abbosh, William C Huang, Neal Shore
Clinical Genitourinary Cancer. 2025-02-04

Authored Content

Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018
Is Imperative Partial Nephrectomy Feasible for Kidney Cancer with Venous Thrombus Involvement? Outcomes of 42 Cases and Matched Pair Analysis with a Large Radical Nephrectomy CohortMay 2018

Press Mentions

What 5 Doctors Are Excited About in Kidney Cancer ResearchSeptember 5th, 2024
UroGen Announces New Data from the OPTIMA II Study That Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder CancerDecember 2nd, 2022
KCCure Represents Patients at AUA 2018May 27th, 2018
Join now to see all